We applied the novel assay to analyze VILIP-1 concentrations in six different diagnostic groups including AD, behavioral variant frontotemporal dementia (bvFTD), PD spectrum (including Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and dementia with Lewy bodies (DLB)), amyotrophic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), and non-neurodegenerative controls (Con). This evidence concerns the gene VSNL1 and Creutzfeldt Jacob disease.